MR3 Health is a dynamic company bringing an innovative combination of service and preventive technology to patients and insurers to assist in dealing with diabetic foot issues, while reducing the cost of healthcare. Although we are a young company, MR3 Health is uniquely positioned for success with a number of resources unknown to most start-ups. These include issued patents, an FDA cleared medical device supported by clinical trials, and a management team with a wealth of business, manufacturing and medical experience.
Diabetes is a rapidly growing problem both in the United States and abroad. According to figures from the Centers for Disease Control (CDC), the prevalence of diabetes in the U.S. doubled over a 20-year period from 1994 to 2015 (see map). Currently, 1 in 10 Americans, a total of 30.3 million, are diagnosed with the disease. Complications, like diabetic neuropathy, lead to nerve damage and loss of sensation in the sole of the foot while inflammation leads to undetected pressure ulcers. In the U.S., about 80 percent of lower limb amputations started off as a diabetic foot ulcer.
The economic burden placed on the U.S. for the costs associated with treatment of diabetes amount to $300 billion annually. Of that, $16 billion represents the combined cost of treating diabetic foot ulcers and lower limb amputations.That figure may include as many as 1 million diabetic foot ulcer treatments (at an average cost of ($13,000 to $18,000 each) and 110,000 lower limb amputations (at an average of $38,000 to $45,000 each).
Without early detection and treatment, ulcers become infected frequently leading to full or partial amputation of the foot or lower limb. Of the estimated 600 million people living with diabetes worldwide, someone suffers an amputation, on average, every 30 seconds.
Most significantly, the life expectancy of a diabetic amputee is less than five years.
MR3 Health offers an effective solution for the prevention of these complications.